메뉴 건너뛰기




Volumn 17, Issue 12, 2011, Pages

Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNα2a shows earlier viral decline than peg-IFNα2b in combination therapy with ribavirin

Author keywords

Chronic hepatitis C; HCV; Peg interferon; Viral kinetics

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

EID: 82755168728     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882127     Document Type: Article
Times cited : (4)

References (39)
  • 1
    • 24344503816 scopus 로고    scopus 로고
    • HCV natural history: The retrospective and prospective in perspective
    • Alter HJ: HCV natural history: the retrospective and prospective in perspective. J Hepatol 2005; 43: 550-52
    • (2005) J Hepatol , vol.43 , pp. 550-552
    • Alter, H.J.1
  • 2
    • 70350614356 scopus 로고    scopus 로고
    • Pegylated IFN-a2a and ribavirin in the treatment of hepatitis C
    • Aghemo A, Rumi MG, Colombo M: Pegylated IFN-a2a and ribavirin in the treatment of hepatitis C. Expert Rev Anti Infect Ther 2009; 7: 925-35
    • (2009) Expert Rev Anti Infect Ther , vol.7 , pp. 925-935
    • Aghemo, A.1    Rumi, M.G.2    Colombo, M.3
  • 3
    • 79751494192 scopus 로고    scopus 로고
    • Virologic response to treatment with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C in children
    • Pawlowska M, Pilarczyk M, Halota W: Virologic response to treatment with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C in children. Med Sci Monit 2010; 16(12): CR616-21
    • (2010) Med Sci Monit , vol.16 , Issue.12
    • Pawlowska, M.1    Pilarczyk, M.2    Halota, W.3
  • 4
    • 24944552848 scopus 로고    scopus 로고
    • Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan
    • Kumada T, Toyoda H, Honda T et al: Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. Intervirology 2006; 49: 112-18
    • (2006) Intervirology , vol.49 , pp. 112-118
    • Kumada, T.1    Toyoda, H.2    Honda, T.3
  • 5
    • 0036830199 scopus 로고    scopus 로고
    • Retreatment of patients with chronic hepatitis C
    • Shiffman ML: Retreatment of patients with chronic hepatitis C. Hepatology 2002; 36: S128-34
    • (2002) Hepatology , vol.36
    • Shiffman, M.L.1
  • 6
    • 34547428001 scopus 로고    scopus 로고
    • Prediction of response of US veterans to treatment for the hepatitis C virus
    • Backus LI, Boothroyd DB, Phillips BR, Mole LA: Prediction of response of US veterans to treatment for the hepatitis C virus. Hepatology, 2007; 46: 37-47
    • (2007) Hepatology , vol.46 , pp. 37-47
    • Backus, L.I.1    Boothroyd, D.B.2    Phillips, B.R.3    Mole, L.A.4
  • 7
    • 37749030473 scopus 로고    scopus 로고
    • Predictions of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors
    • Kanwal F, Hoang T, Spiegel BM et al: Predictions of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors. Hepatology, 2007; 46: 1741-49
    • (2007) Hepatology , vol.46 , pp. 1741-1749
    • Kanwal, F.1    Hoang, T.2    Spiegel, B.M.3
  • 8
    • 77953553818 scopus 로고    scopus 로고
    • Hyperinsulinemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance
    • Bortoletto G, Scribano L, Realdon S et al: Hyperinsulinemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat, 2010; 17: 475-80
    • (2010) J Viral Hepat , vol.17 , pp. 475-480
    • Bortoletto, G.1    Scribano, L.2    Realdon, S.3
  • 9
    • 0032475822 scopus 로고    scopus 로고
    • Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy
    • Neumann AU, Lam NP, Dahari H et al: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science, 1998; 282: 103-7
    • (1998) Science , vol.282 , pp. 103-107
    • Neumann, A.U.1    Lam, N.P.2    Dahari, H.3
  • 10
    • 0031009603 scopus 로고    scopus 로고
    • Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon a
    • Lam NP, Neumann AU, Gretch DR et al: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon a. Hepatology, 1997; 26: 226-31
    • (1997) Hepatology , vol.26 , pp. 226-231
    • Lam, N.P.1    Neumann, A.U.2    Gretch, D.R.3
  • 11
    • 0032102892 scopus 로고    scopus 로고
    • Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy
    • Bekkering FC, Brouwer JT, Leroux-Roels G et al: Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol, 1998; 28: 960-64
    • (1998) J Hepatol , vol.28 , pp. 960-964
    • Bekkering, F.C.1    Brouwer, J.T.2    Leroux-Roels, G.3
  • 12
    • 0035050182 scopus 로고    scopus 로고
    • Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon a2a
    • Zeuzem S, Herrmann E, Lee JH et al: Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon a2a. Gastroenterology, 2001; 120: 1438-47
    • (2001) Gastroenterology , vol.120 , pp. 1438-1447
    • Zeuzem, S.1    Herrmann, E.2    Lee, J.H.3
  • 13
    • 0036208536 scopus 로고    scopus 로고
    • Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon a-2b plus ribavirin
    • Buti M, Sanchez-Avila F, Lurie Y et al: Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon a-2b plus ribavirin. Hepatology, 2002; 35: 930-36
    • (2002) Hepatology , vol.35 , pp. 930-936
    • Buti, M.1    Sanchez-Avila, F.2    Lurie, Y.3
  • 14
    • 78649251945 scopus 로고    scopus 로고
    • A perspective on modeling hepatitis C virus infection
    • Guedj J, Rong L, Dahari H, Perelson AS: A perspective on modeling hepatitis C virus infection. J Viral Hepat, 2010; 17: 825-53
    • (2010) J Viral Hepat , vol.17 , pp. 825-853
    • Guedj, J.1    Rong, L.2    Dahari, H.3    Perelson, A.S.4
  • 15
    • 56749177311 scopus 로고    scopus 로고
    • A hepatitis C viral kinetic model that allows for time-varying drug effectiveness
    • Shudo E, Riberio RM, Talal AH, Perelson AS: A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antivir Ther, 2008; 13: 919-26
    • (2008) Antivir Ther , vol.13 , pp. 919-926
    • Shudo, E.1    Riberio, R.M.2    Talal, A.H.3    Perelson, A.S.4
  • 16
    • 41549108436 scopus 로고    scopus 로고
    • Modeling hepatitis C virus kinetics during treatment with pegylated interferon a-2b: Errors in the estimation of viral kinetic parameters
    • Shudo E, Riberio RM, Perelson AS: Modeling hepatitis C virus kinetics during treatment with pegylated interferon a-2b: errors in the estimation of viral kinetic parameters. J Viral Hepat, 2008; 15: 357-62
    • (2008) J Viral Hepat , vol.15 , pp. 357-362
    • Shudo, E.1    Riberio, R.M.2    Perelson, A.S.3
  • 17
    • 49149090985 scopus 로고    scopus 로고
    • Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells
    • Colombatto P, Ciccorossi P, Maina AM et al: Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells. Clin Pharmacol Ther, 2008; 84: 212-15
    • (2008) Clin Pharmacol Ther , vol.84 , pp. 212-215
    • Colombatto, P.1    Ciccorossi, P.2    Maina, A.M.3
  • 18
    • 33749237156 scopus 로고    scopus 로고
    • First phase viral kinetic parameters and prediction of response to interferon a-2b/ribavirin combination therapy in patients with chronic hepatitis C
    • Makiyama A, Itoh Y, Yasui K et al: First phase viral kinetic parameters and prediction of response to interferon a-2b/ribavirin combination therapy in patients with chronic hepatitis C. Hepatol Res, 2006; 36: 94-99
    • (2006) Hepatol Res , vol.36 , pp. 94-99
    • Makiyama, A.1    Itoh, Y.2    Yasui, K.3
  • 19
    • 64549090121 scopus 로고    scopus 로고
    • Viral kinetic of HCV genotype-4 during pegylated interferon a 2a: Ribavirin therapy
    • Derbala MF, El Dweik NZ, Al Kaabi SR et al: Viral kinetic of HCV genotype-4 during pegylated interferon a 2a: ribavirin therapy. J Viral Hepat, 2008; 15: 591-99
    • (2008) J Viral Hepat , vol.15 , pp. 591-599
    • Derbala, M.F.1    El Dweik, N.Z.2    Al Kaabi, S.R.3
  • 20
    • 75349106114 scopus 로고    scopus 로고
    • Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b
    • Sasase N, Kim SR, Kudo M et al: Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b. Intervirology, 2010; 53: 49-54
    • (2010) Intervirology , vol.53 , pp. 49-54
    • Sasase, N.1    Kim, S.R.2    Kudo, M.3
  • 21
    • 67650132966 scopus 로고    scopus 로고
    • Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin
    • Elefsiniotis IS, Vezali E, Mihas C, Saroglou G: Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Intervirology, 2009; 52: 247-51
    • (2009) Intervirology , vol.52 , pp. 247-251
    • Elefsiniotis, I.S.1    Vezali, E.2    Mihas, C.3    Saroglou, G.4
  • 22
    • 68249154875 scopus 로고    scopus 로고
    • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    • McHutchison JG, Lawitz EJ, Shiffman ML et al: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New Engl J Med, 2009; 361: 580-93
    • (2009) New Engl J Med , vol.361 , pp. 580-593
    • McHutchison, J.G.1    Lawitz, E.J.2    Shiffman, M.L.3
  • 23
    • 44849097562 scopus 로고    scopus 로고
    • Scientific rationale and study design of the individualized dosing efficacy vs. flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: Determining optimal dosing in patients with genotype 1 chronic hepatitis C
    • McHutchison JG, Sulkowski M: Scientific rationale and study design of the individualized dosing efficacy vs. flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat, 2008; 15: 475-81
    • (2008) J Viral Hepat , vol.15 , pp. 475-481
    • McHutchison, J.G.1    Sulkowski, M.2
  • 24
    • 73149116017 scopus 로고    scopus 로고
    • Pharmacotherapy of chronic hepatitis C virus infection-the IDEAL trial: '2b or not 2b (=2a), that is the question'
    • Toyoda H, Kumada T: Pharmacotherapy of chronic hepatitis C virus infection-the IDEAL trial: '2b or not 2b (=2a), that is the question'. Expert Opin Pharmacother, 2009; 10: 2845-57
    • (2009) Expert Opin Pharmacother , vol.10 , pp. 2845-2857
    • Toyoda, H.1    Kumada, T.2
  • 25
    • 33746239302 scopus 로고    scopus 로고
    • Viral kinetics in the treatment of chronic hepatitis C
    • Layden-Almer JE, Cotler SJ, Layden TJ: Viral kinetics in the treatment of chronic hepatitis C. J Hepatol, 2006; 13: 499-504
    • (2006) J Hepatol , vol.13 , pp. 499-504
    • Layden-Almer, J.E.1    Cotler, S.J.2    Layden, T.J.3
  • 26
    • 0041317672 scopus 로고    scopus 로고
    • Viral kinetics in hepatitis C virus: Special patients populations
    • Layden-Almer JE, Layden TJ: Viral kinetics in hepatitis C virus: special patients populations. Semin Liver Dis, 2003; 23(Suppl.1): 29-33
    • (2003) Semin Liver Dis , vol.23 , Issue.SUPPL. 1 , pp. 29-33
    • Layden-Almer, J.E.1    Layden, T.J.2
  • 27
    • 0038820380 scopus 로고    scopus 로고
    • Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin
    • Layden-Almer JE, Ribeiro RM, Wiley T et al: Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology, 2003; 37: 1343-50
    • (2003) Hepatology , vol.37 , pp. 1343-1350
    • Layden-Almer, J.E.1    Ribeiro, R.M.2    Wiley, T.3
  • 28
    • 82755192524 scopus 로고    scopus 로고
    • Association between amino acids 70 and 91 in the HCV core region and second-phase viral decline during antiviral therapy for patients with HCV 1b
    • Nakao R, Yatsuhashi H, Hashimoto S et al: Association between amino acids 70 and 91 in the HCV core region and second-phase viral decline during antiviral therapy for patients with HCV 1b. J Hepatol, 2009; 50; S234
    • (2009) J Hepatol , vol.50
    • Nakao, R.1    Yatsuhashi, H.2    Hashimoto, S.3
  • 29
    • 20644441571 scopus 로고    scopus 로고
    • Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
    • Bodenheimer HC Jr, Lindsay KI, Davis GL et al: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology, 1997; 26: 473-77
    • (1997) Hepatology , vol.26 , pp. 473-477
    • Bodenheimer Jr., H.C.1    Lindsay, K.I.2    Davis, G.L.3
  • 30
    • 0031831349 scopus 로고    scopus 로고
    • Ribavirin monotherapy in patients with chronic hepatitis C: A retrospective study of 95 patients
    • Zoulim F, Haem J, Ahmed SS et al: Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat, 1998; 5: 193-98
    • (1998) J Viral Hepat , vol.5 , pp. 193-198
    • Zoulim, F.1    Haem, J.2    Ahmed, S.S.3
  • 31
    • 10344259671 scopus 로고    scopus 로고
    • Ribavirin treatment for patients with chronic hepatitis C: Result of a placebo-controlled study
    • Dusheiko G, Main J, Thomas H et al: Ribavirin treatment for patients with chronic hepatitis C: result of a placebo-controlled study. J Hepatol, 1996; 25: 591-98
    • (1996) J Hepatol , vol.25 , pp. 591-598
    • Dusheiko, G.1    Main, J.2    Thomas, H.3
  • 32
    • 1542377471 scopus 로고    scopus 로고
    • Antiviral action of ribavirin in chronic hepatitis C
    • Pawlotsky JM, Dahari H, Neumann AU et al: Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology, 2004; 126: 703-14
    • (2004) Gastroenterology , vol.126 , pp. 703-714
    • Pawlotsky, J.M.1    Dahari, H.2    Neumann, A.U.3
  • 33
    • 77950976387 scopus 로고    scopus 로고
    • Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: Viral kinetics and modeling
    • Rong L, Perelson AS: Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. Crit Rev Immunol, 2010; 30: 131-48
    • (2010) Crit Rev Immunol , vol.30 , pp. 131-148
    • Rong, L.1    Perelson, A.S.2
  • 34
    • 0037251550 scopus 로고    scopus 로고
    • Peginterferon a2a (40 kD) plus ribavirin: A review of its use in the management of chronic hepatitis C
    • Keating G, Curran M: Peginterferon a2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs, 2003; 63: 701-30
    • (2003) Drugs , vol.63 , pp. 701-730
    • Keating, G.1    Curran, M.2
  • 35
    • 0036750664 scopus 로고    scopus 로고
    • Pegylated interferons for the treatment of chronic hepatitis C infection
    • Luxon BA, Grace M, Brassard D, Bordens R: Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther, 2002; 24: 1363-83
    • (2002) Clin Ther , vol.24 , pp. 1363-1383
    • Luxon, B.A.1    Grace, M.2    Brassard, D.3    Bordens, R.4
  • 36
    • 35549000195 scopus 로고    scopus 로고
    • Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia
    • Akuta N, Suzuki F, Kawamura Y et al: Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology, 2007; 50: 361-68
    • (2007) Intervirology , vol.50 , pp. 361-368
    • Akuta, N.1    Suzuki, F.2    Kawamura, Y.3
  • 37
    • 70349548852 scopus 로고    scopus 로고
    • IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
    • Suppiah V, Moldovan M, Ahlenstiel G, et al: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet, 2009; 41: 1100-4
    • (2009) Nat Genet , vol.41 , pp. 1100-1104
    • Suppiah, V.1    Moldovan, M.2    Ahlenstiel, G.3
  • 38
    • 70349533037 scopus 로고    scopus 로고
    • Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    • Tanaka Y, Nishida N, Sugiyama M et al: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet, 2009; 41: 1105-9
    • (2009) Nat Genet , vol.41 , pp. 1105-1109
    • Tanaka, Y.1    Nishida, N.2    Sugiyama, M.3
  • 39
    • 70349292099 scopus 로고    scopus 로고
    • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    • Ge D, Fellay J, Thompson AJ et al: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009; 461: 399-401
    • (2009) Nature , vol.461 , pp. 399-401
    • Ge, D.1    Fellay, J.2    Thompson, A.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.